GSA Capital Partners LLP Has $535,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

GSA Capital Partners LLP lowered its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 62.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,113 shares of the company's stock after selling 20,287 shares during the period. GSA Capital Partners LLP's holdings in Vera Therapeutics were worth $535,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in VERA. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after purchasing an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Vera Therapeutics in the second quarter worth approximately $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vera Therapeutics during the second quarter worth approximately $163,000. Ameritas Investment Partners Inc. boosted its stake in shares of Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company's stock valued at $172,000 after purchasing an additional 688 shares during the period. Finally, Cetera Advisors LLC purchased a new position in shares of Vera Therapeutics in the first quarter valued at $235,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Stock Down 0.3 %

Shares of NASDAQ VERA traded down $0.15 during mid-day trading on Wednesday, reaching $45.75. The company had a trading volume of 401,240 shares, compared to its average volume of 907,190. The stock has a fifty day moving average of $43.03 and a two-hundred day moving average of $39.51. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -17.53 and a beta of 1.03. Vera Therapeutics, Inc. has a 12-month low of $12.28 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, equities research analysts expect that Vera Therapeutics, Inc. will post -2.84 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of Vera Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the transaction, the director now directly owns 160,376 shares of the company's stock, valued at approximately $6,737,395.76. This trade represents a 0.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares of the company's stock, valued at $11,548,950. This represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 89,927 shares of company stock worth $3,800,796 over the last 90 days. Insiders own 21.70% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on VERA. Evercore ISI raised shares of Vera Therapeutics to a "strong-buy" rating in a report on Monday, September 16th. Wedbush increased their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a report on Friday, November 8th. Scotiabank assumed coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $60.00 price objective on the stock. Guggenheim increased their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Monday, October 28th. Finally, JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $57.88.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.